Innocoll AG

Innocoll — Merger or Acquisition (April 2017)

13 slides from Innocoll's merger presentation, Apr 27, 2017

  1. Slide 1: Discussion of Rule 2.5 announcement with shareholders

    Discussion of 2.5 announcement with shareholders April #, 2017

  2. Slide 2: Agenda

    Agenda 1 What is the status of the XARACOLL NDA? 2 What is the recommended offer? 3 What alternative options were considered? 4 Why does the INNL Board recommend current offer? 5 What is the structure of the Scheme of Arrangements? 1 2 3 5 4

  3. Slide 3: What is the status of the XARACOLL NDA?

    In October 2016 Innocoll submitted its new drug application (NDA) to the FDA in respect of XARACOLLOn December 29, 2016, Innocoll announced it had received a Refusal to File Letter from the FDAUpon preliminary review, the FDA determined that the application was not sufficiently complete to permit a

  4. Slide 4: What is the status of the XARACOLL NDA? (resubmission timing)

    Innocoll believes that, if adequately financed and successful, such studies may be completed in time for a resubmission of the NDA at the end of 2017Data from these studies, along with additional manufacturing information required to address the new combination product designation and other chemistr

  5. Slide 5: What is the recommended offer?

    Under the terms of the Acquisition, Innocoll Shareholders will be entitled to receive from Gurnet Bidco, a wholly owned subsidiary of Gurnet Point, for each Innocoll share:$1.75 in cash; andup to $4.90 in cash from a contingent value right (“CVR”) which represents a contractual right to receive paym

  6. Slide 6: Contingent value rights payment events

    Pursuant to the terms of the Acquisition, each CVR represents the right to receive the following cash payments from Gurnet Bidco, with each payment conditional upon the achievement of certain events as follows:First CVR Payment EventGurnet Bidco will pay $0.70 in cash per CVR if, on or before Decemb

  7. Slide 7: What alternative options were considered?

    Innocoll’s financial modelling shows that in order to finance its operations through 2019, it would need to raise a significant amount of capital (in excess of $100 million) through equity, debt financings, and U.S. licensing agreementsInnocoll believes there are three alternatives to continue in op

  8. Slide 8: Equity raise and debt financing alternatives

    Equity RaiseAfter the RTF letter, Innocoll Shares have been trading for less than $1.00 per share, with a resulting market capitalization of less than $30 million, the Innocoll Directors believe that Innocoll faces significant obstacles in raising equityAn equity raise of in excess of $100 million r

  9. Slide 9: Why does the Innocoll Board recommend the offer?

    Innocoll Directors believe a sale of Innocoll is the best path forward to realize value for Innocoll Shareholders based on:Potential challenges of raising the required amount of capital through equity financings; andGiven Innocoll’s current valuation and the significant dilution to current Innocoll

  10. Slide 10: Timeframe of the Scheme of Arrangements

    What is the timeframe of the Scheme of Arrangements? 5 August April May June July - Proxy SEC Filing- Engaged transfer agents (Okapi, Continental, Capital) 19 - Share registered by irrevocable/INNL supporters- SEC confirmation (yes/no) review 28 - Panel/1st court hearing approval- Board approves mai

  11. Slide 11: Backup

    INNSCOll Engineering Better Medicines BACKUP

  12. Slide 12: Premium represented by the cash consideration

    The Cash Consideration of $1.75 per Innocoll Share represents a premium of:approximately 120 percent to the closing price of $0.80 per Innocoll Share on March 10, 2017 (being the last dealing day prior to the date on which the anomalous movement in Innocoll’s shares commenced);approximately 37 perce

  13. Slide 13: Irrevocable undertakings to vote in favor

    In addition, Gurnet Point and Gurnet Bidco have received irrevocable undertakings to vote or procure votes in favor of the Scheme Meeting Resolution and the EGM Resolutions (or, if the Acquisition is implemented by way of a Takeover Offer, to accept or procure acceptance of that Takeover Offer) from

Innocoll Holdings — Merger or Acquisition (April 2017) on 6ix